Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON39212
NL-OMON39212
Not yet recruiting
Not Applicable

The effects of neoadjuvant hormonal therapy on the course of PSA and testosterone in patients with low and intermediate risk prostate carcinoma (NEO-ONE) - NHT influence on PSA and testosterone after brachytherapy (NEO-ONE)

TweeSteden ziekenhuis0 sites400 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsprostate carcinomaprostate cancer10038588

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
prostate carcinoma
Sponsor
TweeSteden ziekenhuis
Enrollment
400
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
TweeSteden ziekenhuis

Eligibility Criteria

Inclusion Criteria

  • •These are the inclusioncriteria:
  • •Patients with low and intermediate risk prostate cancer (according to Dutch guidelines)
  • •prostate volume between 35 and 55 cc
  • •a life expectancy of at least 10 years
  • •written informed consent

Exclusion Criteria

  • •These are the exclusion criteria:
  • •Contra\-indication for BT
  • •use of hormone suppressive therapy in the past or surgical castration.
  • •use of 5 alfa reductase in the last 6 months
  • •use of estrogens
  • •cognitive impairments
  • •negative decision for study participation by the hospitals\* urology\-radiotherapy meeting
  • •kidney or liver dysfunction
  • •history of myocardial infarction with present symptoms or CAD\-induced heart failure

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
The effects of pretreatment with androgen blocking hormones before brachytherapy for prostate cancer on the course of PSA and testosterone after treatmentocalized prostate cancerMedDRA version: 14.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-004749-41-NLTweeSteden hospital
Active, not recruiting
Phase 1
Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
EUCTR2020-003575-18-FRINSTITUT DE CANCEROLOGIE DE L'OUEST262
Completed
Phase 2
Effect of hormonal therapy versus no treatment on testicular histopathology and fertility in patients with non-obstructive azoospermianon-obstructive azoospermia.Male infertility
IRCT201612069014N137Vice-chancellor for Research the Technology, Hamadan University of Medical Sciences28
Recruiting
Not Applicable
Retrospective study of the efficacy of hormonal therapy for advanced or recurrent low-grade endometrial stromal sarcomaunresectable advanced or recurrent low-grade endometrial stromal sarcoma
JPRN-UMIN000050780Shizuoka Cancer Center40
Active, not recruiting
Not Applicable
Modulation of response to hormonal therapy with lapatinib and/or metformin in patients with HER2-negative, ER and/or PgR positive metastatic breast cancer with progressive disease after first-line hormonal therapyFemale patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapyMedDRA version: 14.1Level: SOCClassification code 10038604Term: Reproductive system and breast disordersSystem Organ Class: 10038604 - Reproductive system and breast disordersTherapeutic area: Diseases [C] - Cancer [C04]
EUCTR2011-000155-16-ITFONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI